医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Hoya Reports First Quarter Financial Results

2015年07月29日 PM07:37
このエントリーをはてなブックマークに追加


 

TOKYO

HOYA Corporation (TOKYO:7741) today announced financial results for the first quarter ended June 30, 2015. During the quarter, revenues increased by 11.6% to 126,238 million yen compared with the same period last year. Pre-tax profit for the quarter was 30,901 million yen, while profit for this quarter was 23,650 million yen, both of which marked gains of 37.7% and 31.7%, respectively.

In the Information Technology segment, demand for semiconductor- and liquid crystal panel-related products drove sales expansion. On the other hand, sales in volume terms of glass disks for HDDs decreased due to the PC market downturn. Among imaging-related products, the Company is developing applications other than digital cameras, and sales overall held firm. In the Life Care segment, sales in the eyeglass lens business expanded mainly due to expansion in overseas markets. The contact lens retail business reported a major increase recovering from negative impact of Japan’s tax hike last year. In the medical related products businesses, sales of medical endoscopes weakened, however, in part because of the ongoing recovery sales in the intraocular lenses business for cataract surgery, overall sales were generally strong. In addition, along with the positive impact of the depreciation of the yen, segment sales rose year on year.

“Eyeglass business achieved favorable growth. Especially in Europe our steady sales efforts became successful,” said Hiroshi Suzuki, chief executive officer of HOYA. “As for overall business result, we increased profit while revenue declined. This is mainly because we took swift measurement last year such as consolidation of production sites.”

HOYA also announced the forecast for the first six months ending September 30, 2015 as shown below.

 
Revenue and Profit before tax   Three months ended   Variance

( Millions of Yen: Rounded off to the nearest million.)

  Jun. 30,2014   Jun. 30,2015   (%)
Revenue 113,071   126,238 11.6
Profit before tax 22,443 30,901 37.7
  Ratio of profit before tax(%) 19.8% 24.5%
Profit for the quarter 17,962 23,650 31.7
  Ratio of profit for the quarter(%)   15.9%     18.7%      
Profit attributable to owners of the Company 17,798 23,344 31.2
  Ratio of profit attributable to owners of the Company(%)   15.7%     18.5%      
Basic earnings per share (yen) 41.36 55.33
 
Projected Results for the First Half   Six months ended/ending   Variance
( Millions of Yen: Rounded off to the nearest million.)   Sep.30,2014   Sep.30,2015   (%)
Revenue 234,314   250,000 6.7
Profit before tax 56,700 57,000 0.5
Profit for the term 45,285 44,500 -1.7
Profit attributable to owners of the Company   44,948     44,000     -2.1
Profit for the term per share (Yen) 105.30 105.16

*Results are preliminary and unaudited.

 

The full reports are available at http://www.hoya.com

About HOYA

Founded in 1941 in Tokyo, Japan, Hoya is a global med-tech company and the leading supplier of innovative high-tech and medical products. Hoya is active in the fields of healthcare and information technology providing eyeglasses, medical endoscopes, intraocular lenses, optical lenses as well as key components for semiconductor devices, LCD panels and HDDs. With over 150 offices and subsidiaries worldwide, Hoya currently employs a multinational workforce of over 34,000 people. For more information, please visit http://www.hoya.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150729005766/en/

CONTACT

Hoya Group
Akiko Chiba, +81-3-3952-6416
Public Relation
HOYA-pr@hoya.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作